Navigation Links
Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants
Date:11/1/2010

BOSTON, Nov. 1, 2010 /PRNewswire/ -- Researchers studied the treatment of pregnant women with hepatitis B virus (HBV) with Telbivudine in their second to third trimesters. The study concluded that both the mothers benefited from treatment and no transmission of HBV to newborns was detected at 28 weeks postbirth.

The study presenter and co-investigator Calvin Pan, MD, anticipates a "very powerful impact in the field, as hepatitis B is difficult to eradicate and currently there is no treatment modality that can cure the disease. Blocking the vertical transmission from mother to infant will eventually decrease the disease burden in the future generations with the hope to eradicate HBV from the earth."

Current vaccines and HBIG given to a newborn do not work well when the mother has a high viral load and is HBeAg positive. According to Dr. Pan, "Transmission rate to the newborn in this population is about 15 to 30 percent, resulting in a newborn with lifelong HBV infection 90 percent of the time."

For this study, pregnant women with high levels of HBVDNA enrolled in the treatment arm of the study were given 600 mg daily of Telbivudine. All newborns received three doses of hepatitis B vaccine. Patients in the treatment arm achieved sustained virologic response rate (SVR) of 53 percent prior to delivery and 62 percent four weeks after delivery. None of the patients in the control arm achieved SVR at either point.

Only four percent of newborns in the treatment arm tested positive for hepatitis B, whereas 23 percent of newborns from the control group tested positive. None of the patients treated with Telbivudine had to stop treatment due to adverse events. No congenital deformities were observed up to 28 weeks after birth. There were no measurable differences in postpartum health issues for mothers and newborns between the treatment and control groups.

Dr. Pan realizes the limitations of this study: "The infant follow up is limited to 28 weeks after birth. Even though it is good enough to define the failure rate of transmission prevention, the long term safety data for the infant is missing. Hypothetically, antiviral therapy and immunoprophylaxis can be effective in blocking transmission that occurs during late pregnancy or delivery, but the mechanism of intrauterine transmission remains a puzzle. More studies are needed in the field to provide a comprehensive strategy to prevent HBV vertical transmission."  

The message he wants to convey is still a positive one and shows a different way of attacking the problem of HBV. "Because we are struggling in combating the pandemic of hepatitis B worldwide, and frustrated in the limited resources we can allocate for treating our patients," said Dr. Pan, "Maybe we should be putting more efforts and allocating more resources on preventing HBV vertical transmission."

Abstract title:

A Prospective and Open-Label Study for the Efficacy and Safety of Telbivudine(Ltd) in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus (HBV) to the Infants

About the AASLD

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Boston, Massachusetts, October 29-November 2, will bring together more than 7,500 researchers from 55 countries.

A pressroom will be available from October 30 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Haran at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com. Media Contact:: Gregory Bologna703-299-9766gbologna@aasld.org Press Room: October 30 – November 2, 2010Hynes Convention Center, Room 208Telephone: 617-954-3106Researcher: Calvin Pan, MDEmail: cpan11355@yahoo.comPhone: 718-888-7728
'/>"/>

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
2. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
3. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
4. Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer
5. Water Street Healthcare Partners Signs Definitive Agreement to Sell Sierra Scientific Instruments to Given Imaging
6. Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas
7. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
8. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
9. Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill
10. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
11. Survey Finds Mothers Take Childrens Health Into Their Own Hands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... and OR AKIVA, Israel , February ... Ltd., a leader in the field of cartilage ... round on February 5, 2016. The $15 million investment ... a leading Chinese pharmaceutical manufacturer, and was joined by ... Generali Financial Holdings and both the Technion Research & ...
(Date:2/10/2016)... KANSAS CITY, Mo. , Feb. 10, 2016 ... the pharmaceutical industry, recently identified an industry-wide trend ... a tool that allows organizations to efficiently deliver ... surveys, one in 2011 and another in 2015, ... are armed with tablet devices and DSAs, many ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... Guard, to associations of medical professionals throughout the country. The Guard was specifically ... assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , In ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, ... now offering a variety of comprehensive procedures for facial enhancement. The treatments now ... restoration, lip enhancement and nasal reshaping. , As a result, patients can ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former NFL ... a closer look at cases of TBI being managed by their members. The survey ... aging population, and identifies the challenges associated with their care. , During the week ...
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
Breaking Medicine News(10 mins):